Aptevo Therapeutics (APVO) Operating Expenses (2015 - 2026)
Aptevo Therapeutics (APVO) posted Operating Expenses of $6.8 million for Q1 2026, up 14.03% sequentially from $6.0 million in Q4 2025, and up 5.51% YoY from $6.5 million in Q1 2025.
Aptevo Therapeutics (APVO) Operating Expenses (2015 - 2026) Analysis & Trends
Aptevo Therapeutics has reported Operating Expenses for 12 years, with the latest figure at $6.8 million in Q1 2026.
- Quarterly Operating Expenses rose 5.51% year-over-year to $6.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $26.7 million (up 10.66% YoY) and the FY2025 annual result came in at $26.3 million, up 6.95% from the prior year.
- Operating Expenses advanced to $6.8 million in Q1 2026 per APVO's latest filing, from $6.0 million in the prior quarter.
- Over five years, Operating Expenses peaked at $8.7 million in Q1 2022 and troughed at $5.2 million in Q3 2024.
- A 5-year average of $7.0 million and a median of $6.8 million in 2026 frame the typical range for Operating Expenses.
- The sharpest annual moves came in 2024 and 2025: Operating Expenses decreased 26.34% in 2024, then surged 45.98% in 2025.
- Over 5 years, Operating Expenses stood at $7.7 million in 2022, then decreased by 16.92% to $6.4 million in 2023, then fell by 0.03% to $6.4 million in 2024, then slipped by 6.05% to $6.0 million in 2025, then grew by 14.03% to $6.8 million in 2026.
- According to Business Quant data, Operating Expenses over the past three periods registered $6.8 million, $6.0 million, and $7.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | Aptevo Therapeutics | 3.30 Mn | -6.50 Mn | - | 6.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.44 Mn |
| Mar 31, 2026 | 6.84 Mn |
| Dec 31, 2025 | 6.00 Mn |
| Sep 30, 2025 | 7.61 Mn |
| Jun 30, 2025 | 6.23 Mn |
| Mar 31, 2025 | 6.48 Mn |
| Dec 31, 2024 | 6.38 Mn |
| Sep 30, 2024 | 5.21 Mn |
| Jun 30, 2024 | 6.02 Mn |
| Mar 31, 2024 | 6.98 Mn |
| Dec 31, 2023 | 6.38 Mn |
| Sep 30, 2023 | 6.56 Mn |
| Jun 30, 2023 | 8.18 Mn |
| Mar 31, 2023 | 7.76 Mn |
| Dec 31, 2022 | 7.68 Mn |
| Sep 30, 2022 | 7.78 Mn |
| Jun 30, 2022 | 7.56 Mn |
| Mar 31, 2022 | 8.73 Mn |
| Dec 31, 2021 | 7.71 Mn |
| Sep 30, 2021 | 7.85 Mn |